BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 27875633)

  • 1. Design, Synthesis, and Evaluation of Dasatinib-Amino Acid and Dasatinib-Fatty Acid Conjugates as Protein Tyrosine Kinase Inhibitors.
    Tiwari RK; Brown A; Sadeghiani N; Shirazi AN; Bolton J; Tse A; Verkhivker G; Parang K; Sun G
    ChemMedChem; 2017 Jan; 12(1):86-99. PubMed ID: 27875633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel guanidine derivatives targeting leukemia as selective Src/Abl dual inhibitors: Design, synthesis and anti-proliferative activity.
    Moustafa AH; AboulMagd AM; Ali AM; Khodairy A; Marzouk AA; Nafady A; T M Nemr M
    Bioorg Chem; 2024 Jun; 147():107410. PubMed ID: 38688197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, biological evaluation and molecular modeling of novel 2-amino-4-(1-phenylethoxy) pyridine derivatives as potential ROS1 inhibitors.
    Tian Y; Zhang T; Long L; Li Z; Wan S; Wang G; Yu Y; Hou J; Wu X; Zhang J
    Eur J Med Chem; 2018 Jan; 143():182-199. PubMed ID: 29174814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase.
    Shibata N; Shimokawa K; Nagai K; Ohoka N; Hattori T; Miyamoto N; Ujikawa O; Sameshima T; Nara H; Cho N; Naito M
    Sci Rep; 2018 Sep; 8(1):13549. PubMed ID: 30202081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A New Series of Antileukemic Agents: Design, Synthesis, In Vitro and In Silico Evaluation of Thiazole-Based ABL1 Kinase Inhibitors.
    Zeytün E; Altıntop MD; Sever B; Özdemir A; Ellakwa DE; Ocak Z; Ciftci HI; Otsuka M; Fujita M; Radwan MO
    Anticancer Agents Med Chem; 2021; 21(9):1099-1109. PubMed ID: 32838725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
    Konig H; Copland M; Chu S; Jove R; Holyoake TL; Bhatia R
    Cancer Res; 2008 Dec; 68(23):9624-33. PubMed ID: 19047139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological evaluation of novel N-(3-amino-4-methoxyphenyl)acrylamide derivatives as selective EGFR
    Ding S; Dong X; Gao Z; Zheng X; Ji J; Zhang M; Liu F; Wu S; Li M; Song W; Shen J; Duan W; Liu J; Chen Y
    Bioorg Chem; 2022 Jan; 118():105471. PubMed ID: 34798457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.
    Rix U; Hantschel O; Dürnberger G; Remsing Rix LL; Planyavsky M; Fernbach NV; Kaupe I; Bennett KL; Valent P; Colinge J; Köcher T; Superti-Furga G
    Blood; 2007 Dec; 110(12):4055-63. PubMed ID: 17720881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and evaluation of (E)-alpha-benzylthio chalcones as novel inhibitors of BCR-ABL kinase.
    Reddy MVR; Pallela VR; Cosenza SC; Mallireddigari MR; Patti R; Bonagura M; Truongcao M; Akula B; Jatiani SS; Reddy EP
    Bioorg Med Chem; 2010 Mar; 18(6):2317-2326. PubMed ID: 20188579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and anticancer studies of novel aminobenzazolyl pyrimidines as tyrosine kinase inhibitors.
    Chikhale R; Thorat S; Choudhary RK; Gadewal N; Khedekar P
    Bioorg Chem; 2018 Apr; 77():84-100. PubMed ID: 29342447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
    Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents.
    Cai J; Sun M; Wu X; Chen J; Wang P; Zong X; Ji M
    Eur J Med Chem; 2013 May; 63():702-12. PubMed ID: 23567960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of novel dasatinib analogues as potent DDR1 and DDR2 kinase inhibitors.
    Liu L; Hussain M; Luo J; Duan A; Chen C; Tu Z; Zhang J
    Chem Biol Drug Des; 2017 Mar; 89(3):420-427. PubMed ID: 27589335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors.
    Liu S; Jiang Y; Yan R; Li Z; Wan S; Zhang T; Wu X; Hou J; Zhu Z; Tian Y; Zhang J
    Eur J Med Chem; 2019 Oct; 179():358-375. PubMed ID: 31260890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and evaluation of azaacridine derivatives as dual-target EGFR and Src kinase inhibitors for antitumor treatment.
    Cui Z; Chen S; Wang Y; Gao C; Chen Y; Tan C; Jiang Y
    Eur J Med Chem; 2017 Aug; 136():372-381. PubMed ID: 28525838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, Synthesis and Biological Evaluation of Pentacyclic Triterpene Derivatives: Optimization of Anti-ABL Kinase Activity.
    I Ciftci H; O Radwan M; E Ozturk S; Ulusoy NG; Sozer E; E Ellakwa D; Ocak Z; Can M; F S Ali T; I Abd-Alla H; Yayli N; Tateishi H; Otsuka M; Fujita M
    Molecules; 2019 Sep; 24(19):. PubMed ID: 31574910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and evaluation of acridine derivatives as multi-target Src and MEK kinase inhibitors for anti-tumor treatment.
    Cui Z; Li X; Li L; Zhang B; Gao C; Chen Y; Tan C; Liu H; Xie W; Yang T; Jiang Y
    Bioorg Med Chem; 2016 Jan; 24(2):261-9. PubMed ID: 26707846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
    Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
    J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Target modulation by a kinase inhibitor engineered to induce a tandem blockade of the epidermal growth factor receptor (EGFR) and c-Src: the concept of type III combi-targeting.
    Rao S; Larroque-Lombard AL; Peyrard L; Thauvin C; Rachid Z; Williams C; Jean-Claude BJ
    PLoS One; 2015; 10(2):e0117215. PubMed ID: 25658745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quinazolin-4(3
    Mirgany TO; Abdalla AN; Arifuzzaman M; Motiur Rahman AFM; Al-Salem HS
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):2055-2067. PubMed ID: 34551654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.